Retro Biosciences is expanding its phase 1 trial of RTR 242 to 108 participants with higher-dose cohorts, testing a compound designed to restore lysosomal acidity and enhance autophagy—a cellular recycling process that deteriorates with age and is implicated in Alzheimer's and Parkinson's. No major safety signals have emerged, allowing dose escalation to identify therapeutic range.
Key Points
- Phase 1 trial expanded 42% to test higher doses in healthy volunteers
- RTR 242 targets lysosomal acidity restoration and autophagy stimulation
- No major adverse events reported; dose-finding phase ongoing
Longevity Analysis
The trial addresses a core mechanism of neurodegeneration: the age-related decline in cellular recycling capacity. As cells lose their ability to clear damaged proteins and organelles, neurotoxic aggregates accumulate—a hallmark of both Alzheimer's and Parkinson's pathology. By targeting lysosomal function directly, RTR 242 attempts to restore a fundamental housekeeping process rather than treating downstream symptoms. The safety profile through phase 1 supports progression, though efficacy in older adults with established cognitive impairment remains untested and represents the critical next phase for establishing clinical relevance.
Original published by LT Wire.